Differences between Community - and Hospital - acquired urinary tract infections in a tertiary care hospital

New Microbiol. 2020 Jan;43(1):17-21. Epub 2019 Dec 9.

Abstract

The aim of this retrospective study was to highlight the differences in antibiotic resistance between Hospital-acquired and Community-acquired urinary tract infections (UTIs). Antimicrobial UTIs resistance data were collected from March 2011 to March 2018. Uropathogens were identified from 41,715 patients using routine laboratory methods. Differences in antibiotic resistance between Hospital and Community (non-hospitalized) patients were statistically validated. Odds ratio (OR) and p-values was used to determine whether a particular exposure (hospitalization) was a risk factor for a particular outcome (higher antibiotic resistance). We reported a general increase of unnecessary urine cultures in both community and hospital patients. The most representative microorganism isolated from Community (58.2%) and Hospital (47.6%) was E. coli. UTIs causative bacteria in hospitalized patients was more than twice as resistant to Trimetoprim/sulphamethoxazole (OR 2.26) and Imipenem (OR 2.56), for Gram-positive and Gram-negative, respectively, than in Community patients. Nitrofurantoin was the only agent without differences in resistance rate between community and hospital UTIs. Therefore, physicians could use it as a definitive therapy for uncomplicated cystitis and as a prophylactic agent for recurrent uncomplicated cystitis. With this work we provided a general protocol applicable by physicians to select the most suitable, if necessary, UTIs empiric treatment.

Keywords: Community; Infection; Nosocomial; UTI; Urinary; Urine.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteria / drug effects
  • Bacteria / isolation & purification
  • Bacterial Infections* / drug therapy
  • Bacterial Infections* / microbiology
  • Bacterial Infections* / pathology
  • Community-Acquired Infections* / drug therapy
  • Community-Acquired Infections* / microbiology
  • Community-Acquired Infections* / pathology
  • Cross Infection* / drug therapy
  • Cross Infection* / microbiology
  • Cross Infection* / pathology
  • Drug Resistance, Bacterial
  • Humans
  • Retrospective Studies
  • Tertiary Care Centers* / statistics & numerical data
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / microbiology
  • Urinary Tract Infections* / pathology

Substances

  • Anti-Bacterial Agents